Timothy J Whitaker
Chief Tech/Sci/R&D Officer bij SEELOS THERAPEUTICS, INC.
Profiel
Timothy J.
Whitaker is currently the Director at Southern New Hampshire Medical Center and the Chief Medical Officer at Seelos Therapeutics, Inc. He previously worked as the Senior Director-Neuroscience at Wyeth Pharmaceuticals LLC from 1996 to 2004, the VP & Head-Neuroscience Therapeutic Area at Shire Plc from 2004 to 2016, the Chief Medical Officer at Lundbeck Seattle BioPharmaceuticals, Inc. in 2016-2017, and the Associate Professor at the University of Vermont College of Medicine from 1988 to 1996.
He also served as the Chief Medical Officer at Vallon Pharmaceuticals, Inc. from 2018 to 2023.
Dr. Whitaker obtained his undergraduate degree from Duke University and his doctorate from Wake Forest University.
Actieve functies van Timothy J Whitaker
Bedrijven | Functie | Begin |
---|---|---|
SEELOS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Southern New Hampshire Medical Center
Southern New Hampshire Medical Center Hospital/Nursing ManagementHealth Services Southern New Hampshire Medical Center provides health care services. It offers centers for cancer treatment, diabetes education, fertility and childbirth, obesity, sleep disorders, trauma and other programs. The company was founded in 1891 and is headquartered in Nashua, NH. | Director/Board Member | - |
Eerdere bekende functies van Timothy J Whitaker
Bedrijven | Functie | Einde |
---|---|---|
GRI BIOPAR | Chief Tech/Sci/R&D Officer | 21-04-2023 |
ALDER BIOPHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 31-12-2017 |
SHIRE | Corporate Officer/Principal | 01-01-2016 |
Wyeth Pharmaceuticals LLC
Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA. | Corporate Officer/Principal | 01-01-2004 |
University of Vermont College of Medicine | Corporate Officer/Principal | 01-01-1996 |
Opleiding van Timothy J Whitaker
Duke University | Undergraduate Degree |
Wake Forest University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
SEELOS THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
Wyeth Pharmaceuticals LLC
Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA. | Health Technology |
Shire Plc
Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
Southern New Hampshire Medical Center
Southern New Hampshire Medical Center Hospital/Nursing ManagementHealth Services Southern New Hampshire Medical Center provides health care services. It offers centers for cancer treatment, diabetes education, fertility and childbirth, obesity, sleep disorders, trauma and other programs. The company was founded in 1891 and is headquartered in Nashua, NH. | Health Services |
Lundbeck Seattle BioPharmaceuticals, Inc.
Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
Vallon Pharmaceuticals, Inc.
Vallon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Vallon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of proprietary biopharmaceutical products. The firm's primary product is Abuse-Deterrent Amphetamine Immediate and its product pipeline includes ADAIR, ADMIR, ADHD, and Narcolepsy. The company was founded by David C. Baker on January 11, 2018 and is headquartered in Philadelphia, PA. | Health Technology |